US
CA
NZ
UK
AU
IND
Last update at 2025-06-16T15:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Aquestive Therapeutics, Inc. (AQST): Analysts See 245% Upside Potential
Wed 21 May 25, 03:17 PMAquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Mon 12 May 25, 08:01 PMAquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
Wed 09 Apr 25, 11:00 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -54.41000M | -70.53900M | -55.78300M | -66.24600M | -61.37600M |
| Minority interest | - | - | - | - | - |
| Net income | -60.20200M | -90.03600M | -65.36200M | -72.65900M | -61.37600M |
| Selling general administrative | 52.88M | 53.48M | 55.89M | 64.34M | 72.26M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 28.29M | 35.84M | 32.88M | 32.25M | 46.44M |
| Reconciled depreciation | 2.39M | 2.96M | 3.44M | 2.90M | 3.24M |
| Ebit | -42.06600M | -34.67900M | -42.89300M | -52.66800M | -51.62300M |
| Ebitda | -41.96700M | -34.25600M | -42.76100M | -52.03200M | -48.38700M |
| Depreciation and amortization | 0.10M | 0.42M | 0.13M | 0.64M | 3.24M |
| Non operating income net other | - | -13.39900M | 0.13M | -4.26000M | -4.73100M |
| Operating income | -42.06600M | -34.67900M | -42.89300M | -52.66800M | -48.93400M |
| Other operating expenses | 89.75M | 85.51M | 88.74M | 105.28M | 116.36M |
| Interest expense | 12.44M | 22.46M | 13.02M | 9.32M | 7.71M |
| Tax provision | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Interest income | 0.10M | 0.42M | 0.13M | 0.64M | 0.55M |
| Net interest income | -12.34400M | -22.03800M | -12.89000M | -8.68200M | -7.15900M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 5.79M | 19.50M | 9.58M | 6.41M | -4.73100M |
| Total revenue | 47.68M | 50.83M | 45.85M | 52.61M | 67.43M |
| Total operating expenses | 70.36M | 70.52M | 75.78M | 84.92M | 95.38M |
| Cost of revenue | 19.39M | 14.99M | 12.96M | 20.36M | 20.99M |
| Total other income expense net | -12.34400M | -35.86000M | -12.89000M | -13.57800M | -5.28300M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -54.41000M | -70.53900M | -55.78300M | -66.24600M | -61.37600M |
| Net income applicable to common shares | -54.41000M | -70.53900M | -55.78300M | -66.24600M | -61.37600M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 57.42M | 55.67M | 61.99M | 62.88M | 78.48M |
| Intangible assets | 1.28M | 1.44M | 0.05M | 0.10M | 0.15M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1.85M | 2.13M | 3.08M | 3.40M | 3.00M |
| Total liab | 163.91M | 174.23M | 144.13M | 111.38M | 84.60M |
| Total stockholder equity | -106.48700M | -118.55400M | -82.13400M | -48.49700M | -6.12200M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 5.48M | 9.11M | 9.96M | 10.02M | 5.47M |
| Common stock | 0.07M | 0.06M | 0.04M | 0.04M | 0.03M |
| Capital stock | 0.07M | 0.06M | 0.04M | 0.04M | 0.03M |
| Retained earnings | -319.07700M | -311.20700M | -256.79600M | -186.25700M | -130.47400M |
| Other liab | - | 97.56M | 68.67M | 53.10M | 5.71M |
| Good will | - | - | - | - | 0.29M |
| Other assets | 0.00000M | 6.45M | 6.90M | 7.84M | 0.29M |
| Cash | 23.87M | 27.27M | 28.02M | 31.81M | 49.33M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 18.31M | 39.68M | 21.96M | 21.10M | 18.55M |
| Current deferred revenue | 1.55M | 1.51M | 0.77M | 0.69M | 0.81M |
| Net debt | 74.95M | 28.82M | 28.40M | 8.67M | 11.01M |
| Short term debt | 2.35M | 19.11M | 2.92M | 3.30M | - |
| Short long term debt | 0.02M | 18.70M | 2.02M | 2.58M | - |
| Short long term debt total | 98.82M | 56.09M | 56.42M | 40.48M | 60.34M |
| Other stockholder equity | 212.52M | 192.60M | 174.62M | 137.72M | 124.32M |
| Property plant equipment | - | 7.90M | 5.05M | 6.87M | 9.73M |
| Total current assets | 40.97M | 39.89M | 47.26M | 44.62M | 68.31M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | -119.98900M | -82.18500M | -48.59900M | -6.27500M |
| Short term investments | - | - | - | - | - |
| Net receivables | 8.47M | 4.70M | 12.12M | 6.96M | 13.13M |
| Long term debt | 27.51M | 33.45M | 51.55M | 34.33M | 60.34M |
| Inventory | 6.77M | 5.78M | 4.04M | 2.46M | 2.86M |
| Accounts payable | 8.93M | 9.95M | 8.31M | 7.09M | 12.27M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | -38.04400M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.04M | 0.04M | 0.03M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -256.79600M | -186.25700M | -130.47400M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1.44M | 6.45M | 6.90M | 7.84M | 0.29M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 16.45M | 15.79M | 14.73M | 18.26M | 10.16M |
| Capital lease obligations | 5.79M | 3.94M | 2.85M | 3.57M | - |
| Long term debt total | - | - | - | - | 60.34M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -2.52400M | -0.91300M | -0.51700M | -0.66300M | -1.82400M |
| Change to liabilities | 1.63M | 3.94M | -3.03300M | -5.52500M | 10.97M |
| Total cashflows from investing activities | - | -0.91300M | -0.51700M | -0.66300M | -1.82400M |
| Net borrowings | - | - | 22.34M | 13.11M | -4.76800M |
| Total cash from financing activities | 11.56M | 30.11M | 28.46M | 49.60M | 58.03M |
| Change to operating activities | -0.27800M | 1.26M | -7.95300M | -0.62000M | -0.85900M |
| Net income | -54.41000M | -70.53900M | -55.78300M | -66.24600M | -61.37600M |
| Change in cash | -0.75100M | -3.78300M | -17.51900M | -11.27300M | 43.22M |
| Begin period cash flow | 28.02M | 31.81M | 49.33M | 60.60M | 17.38M |
| End period cash flow | 27.27M | 28.02M | 31.81M | 49.33M | 60.60M |
| Total cash from operating activities | -9.78900M | -32.97900M | -45.45900M | -60.21000M | -12.99100M |
| Issuance of capital stock | 13.56M | 29.78M | 6.21M | 39.32M | 68.71M |
| Depreciation | 2.39M | 2.96M | 3.44M | 2.90M | 3.24M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -1.74300M | -1.57700M | 0.40M | 2.58M | -1.42700M |
| Change to account receivables | - | -4.93900M | 1.20M | -7.43500M | -0.40900M |
| Sale purchase of stock | - | 30.12M | 6.21M | 39.32M | 68.83M |
| Other cashflows from financing activities | 0.03M | 0.33M | 46.99M | 63.23M | -10.67900M |
| Change to netincome | - | 20.34M | 6.77M | 12.33M | 35.32M |
| Capital expenditures | 2.52M | 0.91M | 0.52M | 0.66M | 1.82M |
| Change receivables | - | -5.35300M | 6.17M | -6.81500M | -0.40900M |
| Cash flows other operating | - | 13.51M | -6.01500M | -1.36600M | -1.13700M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | -3.78300M | -17.51900M | -11.27300M | 43.22M |
| Change in working capital | 32.01M | -1.73000M | -4.41300M | -11.12400M | 8.00M |
| Stock based compensation | 4.38M | 6.82M | 6.58M | 7.07M | 29.94M |
| Other non cash items | 5.85M | 15.69M | 4.71M | 2.29M | 1.93M |
| Free cash flow | -12.31300M | -33.89200M | -45.97600M | -60.87300M | -14.81500M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AQST Aquestive Therapeutics Inc |
0.06 1.75% | 3.48 | - | - | 6.95 | - | 7.12 | 304.84 |
| ZTS Zoetis Inc |
1.67 1.02% | 166.00 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
0.23 0.87% | 26.61 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
-4.25 3.12% | 132.00 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.075 0.49% | 15.12 | 32.67 | 11.53 | 0.01 | 0.87 | 0.02 | 0.07 |
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
30 Technology Drive, Warren, NJ, United States, 07059
| Name | Title | Year Born |
|---|---|---|
| Mr. Daniel Barber | CEO, Pres & Director | 1976 |
| Mr. A. Ernest Toth Jr. | Sr. VP & CFO | 1959 |
| Mr. Keith J. Kendall | Consultant | 1958 |
| Mr. Alexander Mark Schobel | Chief Innovation & Technology Officer | 1959 |
| Ms. Lori J. Braender BSBA, Esq., J.D. | Sr. VP & Gen. Counsel | 1956 |
| Dr. Eric Dadey Ph.D. | Sr. Vice-Pres of R&D | NA |
| Mr. Peter E. Boyd | Sr. VP of Clinical Operations & Information Technology | 1965 |
| Mr. Kenneth W. Marshall | Sr. VP & Chief Commercial Officer | 1959 |
| Dr. Kenneth Truitt M.D. | Chief Medical Officer | NA |
| Mr. Robert Charles Arnold | VP of Fin., Controller & Assistant Sec. | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...